Dave’s IBD SmartSelect Composite Rating recently jumped from 94 to 97, reflecting fresh recognition for the stock’s performance. The news, reported by Investor’s Business Daily, places Dave in the noteworthy 95-plus rating category.
Composite Rating For Dave Rises To 97
Key Takeaways:
- Dave’s Composite Rating rose from 94 to 97
- The rating surpasses the 95+ mark
- Published by Investor’s Business Daily
- The story was released on Tuesday, November 11, 2025
- This achievement highlights Dave’s elevated standing among higher-rated stocks
What Changed
The IBD SmartSelect Composite Rating for Dave moved up from 94 to 97 on Tuesday. This latest update illustrates an upward trend, hinting at potential strength or market confidence in Dave’s performance.
Why It Matters
A Composite Rating hovering in the mid-90s places a stock in an elite category. According to Investor’s Business Daily’s metrics, achieving a 95+ rating often signals that a company’s technical and fundamental factors are outperforming the majority of other stocks assessed.
Source and Timing
This announcement was shared by Investor’s Business Daily on November 11, 2025. While the full content of the story is available only in paid plans, the key insight is that Dave has now entered a higher echelon of IBD-rated stocks.
Placing Dave in Context
Crossing the 95 threshold sets Dave apart within a competitive field of business stocks. The IBD SmartSelect Composite Rating is widely recognized as an influential measure for many investors looking for top-tier equity picks. Dave’s jump provides fresh evidence of the company’s evolving market position.